House lawmaker raises new concerns over FDA’s ultra-fast drug review program

By MATTHEW PERRONE

WASHINGTON (AP) — A Democratic lawmaker raised new concerns about a Food and Drug Administration program designed to drastically shorten the review of certain drugs, including whether senior officials involved in the effort are complying with federal ethics rules.

Related Articles

• Trump accused of distorting history of Mexican-American War to justify heavy hand in Latin America
• Federal immigration officials scout warehouses as they eye more detention space
• Read Entire Article